Nxera Pharma (SOLTF) News Today $10.53 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 9, 2024 | globenewswire.comNxera Pharma Webinar Presentation for Q2 FY2024 Financial ResultsJune 26, 2024 | globenewswire.comNxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D MilestoneJune 18, 2024 | globenewswire.comNxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023May 30, 2024 | globenewswire.comNxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic AreaMay 9, 2024 | finance.yahoo.comNxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsMay 9, 2024 | globenewswire.comNxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024April 29, 2024 | msn.comFDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency DisorderApril 17, 2024 | finance.yahoo.comNxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU PlanApril 15, 2024 | msn.comNxera and Handok partner for PIVLAZ supply in South KoreaApril 15, 2024 | nasdaq.comNxera Pharma Announces Supply And Distribution Deal With Handok For PIVLAZ In South KoreaApril 15, 2024 | finance.yahoo.comNxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South KoreaApril 8, 2024 | finance.yahoo.comNxera Pharma joins the World Orphan Drug AllianceApril 3, 2024 | finance.yahoo.comNxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APACMarch 31, 2024 | globenewswire.comNxera Pharma is the New Name for Sosei GroupMarch 27, 2024 | finance.yahoo.comSosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera PharmaMarch 20, 2024 | finance.yahoo.comSosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel DiseaseMarch 11, 2024 | finance.yahoo.comBoehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophreniaMarch 6, 2024 | finance.yahoo.comSosei Heptares to receive US$2.5 million milestone payment from Formosa PharmaceuticalsMarch 1, 2024 | finance.yahoo.comSosei Group Corporation (SOLTF)February 15, 2024 | globenewswire.comSosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head OfficeFebruary 13, 2024 | finance.yahoo.comSosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023January 22, 2024 | finance.yahoo.comSosei Heptares Webinar Presentation for FY2023 Financial ResultsJanuary 5, 2024 | finance.yahoo.comSosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating OfficerDecember 21, 2023 | finance.yahoo.comSosei Heptares to Present at 42nd Annual J.P. Morgan Healthcare ConferenceDecember 7, 2023 | finance.yahoo.comSosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South KoreaDecember 6, 2023 | finance.yahoo.comSosei Heptares’ Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical StudiesNovember 24, 2023 | finance.yahoo.comSosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel DiseaseNovember 14, 2023 | morningstar.comSosei Group Corp 4565November 10, 2023 | msn.comSosei Group reports Q3 resultsNovember 10, 2023 | finance.yahoo.comSosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023November 10, 2023 | finance.yahoo.comSosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal DiseasesNovember 7, 2023 | finance.yahoo.comSosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2023November 5, 2023 | finance.yahoo.comSosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 TrialOctober 31, 2023 | finance.yahoo.comSosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of InsomniaOctober 31, 2023 | finance.yahoo.comSosei Heptares Will Receive US$3.75 Million Payment in Multi-Target PartnershipOctober 25, 2023 | finance.yahoo.comSosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development ProgressOctober 18, 2023 | finance.yahoo.comSosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023October 10, 2023 | msn.comSosei and PharmEnable collaborate on another neurological drugOctober 4, 2023 | finance.yahoo.comSosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic DevelopmentSeptember 20, 2023 | finance.yahoo.comSosei Heptares Adds World-leading Expertise to its Scientific Advisory BoardAugust 10, 2023 | finance.yahoo.comSosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732August 4, 2023 | finance.yahoo.comSosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023July 21, 2023 | reuters.comSosei buys Idorsia Pharmaceuticals' Japan, Korea units for $466 million - NikkeiJune 27, 2023 | marketwatch.comSosei Group Shares Indicated Lower After Partner Pfizer Terminates Diabetes Drug DevelopmentJune 3, 2023 | msn.comSosei Group (TYO:4565) Price Target Increased by 5.50% to 3,351.43April 5, 2023 | finance.yahoo.comSosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ MeetingMarch 18, 2023 | finance.yahoo.comSosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime MarketDecember 22, 2022 | reuters.comSosei Group CorpNovember 8, 2022 | finance.yahoo.comPrecisionLife to Evaluate Precision Medicine Potential of Sosei Heptares Neuroscience GPCR TargetSeptember 17, 2022 | investing.comSosei Group Corp (4565) Get Nxera Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SOLTF and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here SOLTF Media Mentions By Week SOLTF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SOLTF News Sentiment▼0.000.62▲Average Medical News Sentiment SOLTF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SOLTF Articles This Week▼00▲SOLTF Articles Average Week Get Nxera Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SOLTF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Algernon Pharmaceuticals News ALK-Abelló A/S News Alpha Tau Medical News Arno Therapeutics News Artelo Biosciences News Ascletis Pharma News Awakn Life Sciences News AXIM Biotechnologies News BerGenBio ASA News BriaCell Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:SOLTF) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nxera Pharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nxera Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.